DPP-4 inhibitors

DRUG11 trials

Conditions

Arterial StiffnessDiabetesDiabetes Mellitus, Type 2GlycocalyxIncretinomimeticsPancreasType 2 DiabetesType 2 Diabetes Mellitus

Phase 4

Roux-en-Y Gastric Bypass for BMI 27-32 Type 2 Diabetes Versus Best Medical Treatment

CompletedNCT02041234

Khoo Teck Puat HospitalType II Diabetes in Subjects BMI 27 to 32

Start: 2014-02-28End: 2022-06-30Target: 40Updated: 2022-06-23

Efficacy in Controlling Glycaemia With Victoza® (Liraglutide) as add-on to Metformin vs. OADs as add-on to Metformin After up to 104 Weeks of Treatment in Subjects With Type 2 Diabetes

CompletedNCT02730377

Novo Nordisk A/SDiabetes, Diabetes Mellitus, Type 2

Start: 2016-03-28End: 2019-08-12Updated: 2020-07-07

Unknown Phase

Clinical study examining effect of DPP-4 inhibitors on postprandial hyperlipidemia

Active, not recruitingJPRN-UMIN000010177

Shimane University Faculty of MedicineType 2 diabetes mellitus

Start: 2013-04-01Target: 30Updated: 2025-07-18

Pathophysiological Study of the Increase in Pancreatic Volume in Type 2 Diabetes Treatments.

TerminatedNCT02244164

Erasme University HospitalIncretinomimetics, Pancreas, Type 2 Diabetes

Start: 2014-10-31End: 2023-02-13Updated: 2023-02-16

Incretin-based Drugs and the Risk of Heart Failure

CompletedNCT02456428

Canadian Network for Observational Drug Effect Studies, CNODESType 2 Diabetes Mellitus

Start: 2014-03-31End: 2015-05-31Updated: 2016-04-19

Incretin-based Drugs and Pancreatic Cancer

CompletedNCT02475499

Canadian Network for Observational Drug Effect Studies, CNODESDiabetes Mellitus, Type 2

Start: 2014-03-31End: 2015-04-30Updated: 2016-03-14

Incretin-based Drugs and Acute Pancreatitis

CompletedNCT02476760

Canadian Network for Observational Drug Effect Studies, CNODESDiabetes Mellitus, Type 2

Start: 2014-03-31End: 2015-04-30Updated: 2016-11-03

Post-authorisation Safety Study in Patients With Type 2 Diabetes to Assess the Risk of Liver Injury, Kidney Injury, Urinary Tract and Genital Infections, and Diabetic Ketoacidosis in Patients Treated With Empagliflozin, Compared to DPP-4 Inhibitors

CompletedNCT02864914

Boehringer IngelheimDiabetes Mellitus, Type 2

Start: 2016-03-15End: 2022-07-29Updated: 2024-11-15

Empa PASS on Urinary Tract Malignancies

CompletedNCT03464045

Boehringer IngelheimDiabetes Mellitus, Type 2

Start: 2016-11-16End: 2024-03-11Updated: 2025-04-20

Use of Incretins in Diabetic Patients

CompletedNCT03486964

University of PaviaDiabetes Mellitus, Type 2

Start: 2018-03-27End: 2021-05-30Updated: 2022-05-24

The Effect of Combined Dulaglutide and Dapagliflozin Treatment vs DPP-4 Inhibitors in Endothelial and Vascular Function in Patients With Type 2 Diabetes Mellitus and Albuminuria

Active, not recruitingNCT06611904

Attikon HospitalArterial Stiffness, Glycocalyx, Urine Albumin (UAlb)

Start: 2018-02-01End: 2024-12-15Updated: 2024-09-25

Journal of Clinical Medicine2024-12-10

Roux-en-Y gastric bypass versus best medical treatment for type 2 diabetes mellitus in adults with body mass index between 27 and 32 kg/m<sup>2</sup>: A 5-year randomized controlled trial.

2022-05-0216 citations

Maintenance of glycaemic control with liraglutide versus oral antidiabetic drugs as add‐on therapies in patients with type 2 diabetes uncontrolled with metformin alone: A randomized clinical trial in primary care ( <scp>LIRA‐PRIME</scp> )

Diabetes Obesity and Metabolism2021-10-0914 citations

922-P: LIRA-PRIME: A Randomized Trial in Primary Care Settings of Liraglutide vs. OAD for Glycemic Control in Patients with Type 2 Diabetes Not in Control on Metformin

Diabetes2020-06-011 citations

LIRA-PRIME Trial Design and Baseline Data—Efficacy in Controlling Glycemia with Liraglutide in a Primary Care Setting

Diabetes2018-06-22

A Multicenter Observational Study of Incretin-based Drugs and Heart Failure

New England Journal of Medicine2016-03-23220 citations

DPP-4 inhibitors

Sponsors

Conditions

Phase 4

Unknown Phase

Related Papers